Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. It happens when the protective cartilage that cushions your bones wears down over time. Osteoarthritis most commonly affects hands, knees, hips, and spine. Researchers and clinicians from BHI Therapeutic Sciences, USA and Blue Horizon International, Slovakia recently concluded cell-based therapy shows promising results in the regeneration of injured cartilage and serves as an anti-inflammatory for the affected joint.
The paper, “A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis” was recently published in the Journal of Clinical Medicine Research.
“Our study of 350 subjects with hip and knee osteoarthritis showed a significant improvement in pain levels and mobility at 3, 6, and 12 months compared to 7 days after autologous stromal vascular fraction (SVF) cell therapy,” said Brian Mehling, M.D., one of the authors of the study and the chief medical officer of BHI Therapeutic Sciences.
The study was approved by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM-2-17-137) and by the Ministry of Health of the Slovak Republic.
“The treatment demonstrated a strong safety profile with no severe adverse events or complications reported,” said Marina Manvelyan, Ph.D., clinical research scientist at BHI Therapeutic Sciences. “Interestingly, the results of the study show that SVF cell therapy was more effective in subjects with arthritis stage III compared to arthritis stages I, II, and IV,” she added.
The authors of the paper are Brian Mehling, Milan Hric, Adriana Salatkova, Robert Vetrak, Doreen Santora, Miriama Ovariova, Renata Mihalyova, and Marina Manvelyan.
BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.
The Journal of Clinical Medicine is an international, open access, and peer-reviewed journal that concentrates on general medical research and clinical practice. The journal aims to publish scientifically written, evidence-based articles from all disciplines of medical sciences and clinical practice, and nursing, preventive medicine, epidemiology, healthcare research, etc. All articles are rigorously peer-reviewed. The journal is indexed in PubMed and PubMed Central (PMC, US National Library of Medicine National Institutes of Health).
To read the study, visit bluehorizonstemcells.com.
Researchers need to modify genes in cells if they are to find out about life’s inner workings. This used to be time-consuming, difficult and sometimes impossible work. Using the CRISPR/Cas9 genetic scissors, it is now possible to change the code of life over the course of a few weeks. Emmanuelle Charpentier and Jennifer A. Doudna have discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants and microorganisms with extremely high precision. This technology has had a revolutionary impact on the life sciences, is contributing to new cancer therapies and may make the dream of curing inherited diseases come true.
LA TOKEN has just announced what could be arguably the most appealing Initial Exchange Offering in the past decade.
It features a stem cell technology backed coin named “Stemy Coin” that is seeking FDA approval for COVID 19 stem cell treatment solutions based not only on the immunomodulatory and anti-inflammatory capacity of stem cells, but also regeneration and reconstruction of damaged tissues.
BHI and Stem Cell Biotech have successfully treated 34 coronavirus patients in Wuhan. This Stem Cell technology has also been proven to effectively address cancer, strokes, heart attacks, diabetes, kidney, liver, and lung disease. GDIH First Response and Stem Cell Biotech will be rolling out 100 clinics around the world, in partnership BHI to combat Covid-19 worldwide. This could be the fastest rising digital currency in the blockchain industry.
HAPPY NURSES WEEK!
The theme for National Nurses Week in 2020 is Compassion|Expertise|Trust.
National Nurses Week is celebrated annually from May 6, also known as National Nurses Day, through May 12, the birthday of Florence Nightingale, the founder of modern nursing. This week is devoted to highlighting the diverse ways in which registered nurses work to improve health care.
We have never been able to repay nurses for all the work they do. For how thankful we’ll always be, nothing can repay the sacrifices they make in supporting doctors, consoling families, and being friends to patients. They make doctor visits and hospital stays a little more compassionate. This is all in addition to their actual jobs, which require tremendous skill and years of education, all of which have been put to the ultimate test in light of the novel coronavirus pandemic.
What if stem cell treatments could help those with COVID-19?
What if pneumonia brought on by the virus could be cured?
That’s what we here at Blue Horizon are trying to find out. Our previous studies have shown that mesenchymal stem cells from the human umbilical cord have immunomodulatory, antimicrobial, anti-inflammatory and tissue repair functions, being a great potential for the prevention and treatment of viral diseases.
Presently we are in the process of submission and obtaining an endorsement from the Food and Drug Administration (FDA) to initiate the clinical trial of the human umbilical cord-derived stem cell administration in patients with severe COVID-19 pneumonia.
Application of the high-quality clinical-grade stem cell source is critical for the successful development and conduct of our study. We are seeking funding to incorporate high-quality stem cells in our study and initiate FDA endorsed clinical trials.
For more information, please visit www.bluehorizonfoundation.org or email us at firstname.lastname@example.org